Skip to main content

REVIEW article

Front. Ophthalmol.
Sec. Inflammatory Eye Diseases
Volume 4 - 2024 | doi: 10.3389/fopht.2024.1412930
This article is part of the Research Topic Update on non infectious Uveitis treatment: anti TNF and beyond View all articles

Update on non-infectious uveitis treatment: Anti-TNF-alpha and beyond

Provisionally accepted
Khushboo Chauhan Khushboo Chauhan 1Mudit Tyagi Mudit Tyagi 2*
  • 1 Smt. Kanuri Santhamma Center for Vitreo Retinal Diseases, LV Prasad Eye Institute, Hyderabad, Andhra Pradesh, India
  • 2 L V Prasad Eye Institute, Hyderabad, India

The final, formatted version of the article will be published soon.

    Non-infectious uveitis (NIU) encompasses a range of conditions marked by inflammation within various layers of the eye. NIU is a significant contributor to irreversible vision loss among the working-age population in developed countries. The aim of treating uveitis is to manage inflammation, prevent its recurrences and to restore or salvage vision. Presently, the standard treatment protocol for NIU involves initiating corticosteroids as the primary therapeutic agents, although more aggressive approaches and steroid sparing agent may be necessary in certain cases. These advanced treatments option include synthetic immunosuppressants like antimetabolites, calcineurin inhibitors and alkylating agents.For patients who exhibit an intolerance or resistance to corticosteroids and conventional immunosuppressive therapies, biologic agents have emerged as a promising alternative.Notably, among the biologic treatments evaluated, TNF-α inhibitors, anti-CD20 therapy and alkylating agents have shown considerable efficacy. In this review, we delve into the latest evidence surrounding the effectiveness of biologic therapy and introduce novel therapeutic strategies targeting immune components as potential avenues for advancing treatment of NIU.

    Keywords: Non-infectious uveitis (NIU), TNF alpha inhibitors, mTOR inhibitors, rituximab, JAK inhibitors, PDE-4 inhibitors, interleukin inhibitors, ACTH analogues

    Received: 06 Apr 2024; Accepted: 16 Jul 2024.

    Copyright: © 2024 Chauhan and Tyagi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Mudit Tyagi, L V Prasad Eye Institute, Hyderabad, India

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.